Quark’s joint venture Riboquark announces the enrollment of the 1st ever Patient in China for a pivotal clinical trial with a siRNA drug candidate
RiboQuark Pharmaceutical Technology Co., Ltd., Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007.
Kunshan, China, 13/Nov/2017 – Kunshan RiboQuark Pharmaceutical Technology Co., Ltd. (“RiboQuark”), a Chinese-foreign equity joint venture and clinical stage pharmaceutical […]